In patients who developed cutaneous immune-related adverse events, researchers compared outcomes for those who received ...

Among modern cancer therapies, immune checkpoint inhibitors (ICI) are among the most successful treatment methods. These ...

Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...

New data show hip osteoarthritis does not raise the risk of immune checkpoint inhibitor–induced inflammatory arthritis, while ...

Initiation of phase 1 portion of the trial planned in 2H 2026-Phase 2 portion of the trial will initiate development of the elraglusib tablet in ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

Degrader of cancer protein IDO1 prevents cancer immune suppression by cancer and offers promising strategy to support existing immunotherapies ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy. (HealthDay News) — Patients with cancer aged 65 years and older receiving immune ...